Frazier Life Sciences Management as of Sept. 30, 2024
Portfolio Holdings for Frazier Life Sciences Management
Frazier Life Sciences Management holds 53 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals (MIRM) | 10.3 | $256M | 6.6M | 39.00 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 8.6 | $213M | 13M | 16.60 | |
| Phathom Pharmaceuticals (PHAT) | 7.3 | $183M | 10M | 18.08 | |
| Krystal Biotech (KRYS) | 7.2 | $180M | 989k | 182.03 | |
| Mbx Biosciences (MBX) | 6.2 | $156M | 6.0M | 25.98 | |
| Rhythm Pharmaceuticals (RYTM) | 5.1 | $127M | 2.4M | 52.39 | |
| Vaxcyte (PCVX) | 4.0 | $101M | 879k | 114.27 | |
| Verona Pharma Sponsored Ads (VRNA) | 3.9 | $97M | 3.4M | 28.77 | |
| Bridgebio Pharma (BBIO) | 3.8 | $96M | 3.8M | 25.46 | |
| Disc Medicine (IRON) | 3.5 | $86M | 1.8M | 49.14 | |
| Arcutis Biotherapeutics (ARQT) | 3.3 | $82M | 8.8M | 9.30 | |
| Edgewise Therapeutics (EWTX) | 3.0 | $76M | 2.8M | 26.69 | |
| Anaptysbio Inc Common (ANAB) | 3.0 | $74M | 2.2M | 33.50 | |
| Erasca (ERAS) | 2.1 | $53M | 19M | 2.73 | |
| Tarsus Pharmaceuticals (TARS) | 2.1 | $52M | 1.6M | 32.89 | |
| Agios Pharmaceuticals (AGIO) | 1.9 | $46M | 1.0M | 44.43 | |
| Revolution Medicines (RVMD) | 1.8 | $45M | 998k | 45.35 | |
| Soleno Therapeutics (SLNO) | 1.8 | $44M | 876k | 50.49 | |
| Kalvista Pharmaceuticals (KALV) | 1.7 | $43M | 3.7M | 11.58 | |
| Oric Pharmaceuticals (ORIC) | 1.7 | $43M | 4.1M | 10.25 | |
| Ultragenyx Pharmaceutical (RARE) | 1.4 | $35M | 634k | 55.55 | |
| Savara (SVRA) | 1.4 | $35M | 8.2M | 4.24 | |
| Cg Oncology (CGON) | 1.2 | $29M | 770k | 37.73 | |
| Rocket Pharmaceuticals (RCKT) | 1.1 | $27M | 1.5M | 18.47 | |
| Trevi Therapeutics (TRVI) | 1.0 | $25M | 7.4M | 3.34 | |
| Mereo Biopharma Group Spon Ads (MREO) | 0.8 | $21M | 5.1M | 4.11 | |
| Silence Therapeutics Ads (SLN) | 0.8 | $21M | 1.1M | 18.18 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $20M | 133k | 149.31 | |
| Hillevax | 0.7 | $19M | 11M | 1.76 | |
| Merus N V (MRUS) | 0.7 | $19M | 373k | 49.96 | |
| Tyra Biosciences (TYRA) | 0.7 | $17M | 731k | 23.51 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.7 | $17M | 4.6M | 3.63 | |
| Alkermes SHS (ALKS) | 0.6 | $16M | 576k | 27.99 | |
| Immatics SHS (IMTX) | 0.6 | $16M | 1.4M | 11.41 | |
| Oruka Therapeutics (ORKA) | 0.5 | $12M | 477k | 24.51 | |
| Lexeo Therapeutics (LXEO) | 0.5 | $11M | 1.3M | 9.04 | |
| Design Therapeutics (DSGN) | 0.4 | $10M | 1.9M | 5.38 | |
| Cogent Biosciences (COGT) | 0.4 | $10M | 937k | 10.80 | |
| Macrogenics (MGNX) | 0.4 | $9.9M | 3.0M | 3.29 | |
| Day One Biopharmaceuticals I (DAWN) | 0.4 | $9.6M | 690k | 13.93 | |
| Allogene Therapeutics (ALLO) | 0.3 | $8.0M | 2.9M | 2.80 | |
| Puma Biotechnology (PBYI) | 0.3 | $7.8M | 3.1M | 2.55 | |
| Adverum Biotechnologies Com New (ADVM) | 0.3 | $7.5M | 1.1M | 7.02 | |
| 89bio (ETNB) | 0.3 | $7.4M | 1.0M | 7.40 | |
| ACADIA Pharmaceuticals (ACAD) | 0.3 | $7.2M | 470k | 15.38 | |
| Arvinas Ord (ARVN) | 0.3 | $7.0M | 285k | 24.63 | |
| Pepgen (PEPG) | 0.2 | $6.0M | 703k | 8.55 | |
| Elevation Oncology (ELEV) | 0.1 | $3.6M | 6.0M | 0.60 | |
| Newamsterdam Pharma Company *w Exp 11/22/202 (NAMSW) | 0.1 | $3.5M | 500k | 7.00 | |
| Immunocore Hldgs Ads (IMCR) | 0.1 | $3.4M | 109k | 31.13 | |
| Nuvation Bio Com Cl A (NUVB) | 0.1 | $2.8M | 1.2M | 2.29 | |
| Aclaris Therapeutics (ACRS) | 0.0 | $304k | 264k | 1.15 | |
| Pieris Pharmaceuticals Com New | 0.0 | $267k | 16k | 16.74 |
